| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | navitoclax:pluripotin (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | I-BET-762 | GDSC1000 | pan-cancer | AAC | 0.0083 | 0.8 |
| mRNA | GDC-0941 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | BRD-K66453893 | CTRPv2 | pan-cancer | AAC | 0.0089 | 0.8 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.0093 | 0.8 |
| mRNA | SB 216763 | GDSC1000 | pan-cancer | AAC | -0.011 | 0.8 |